Patients | Sex | Family history | Age at onset (years) | Symptoms | Duration symptoms (years) | L-dopa response | Progression | Dysk | Fluct | H & Y | LRRK2 mutations |
1 | M | - | 48 | R | 3 | G | ++ | - | - | 2.5 | p.Gly2019Ser |
2 | F | - | 39 | T-UL | 19 | G | + | + | + | 3 | - |
3 | M | Mt-GF | 47 | T-Uni | 20 | G | ++ | + | + | 3 | p.Gly2019Ser |
4 | M | Mt | 24 | A | 3 | Und | Und | - | - | 1.5 | - |
5 | M | - | 46 | T-UL | 6 | Und | Und | - | - | 1 | - |
6 | M | - | 38 | T-UL | 26 | G | ++ | + | + | 4 | - |
7 | M | Mt-Un | 49 | T-UL | 10 | G | + | + | - | 2 | - |
8 | F | - | 48 | A,R | 17 | R | +++ | + | + | 4 | - |
9 | M | F-GF | 48 | T-bi | 20 | R | + | - | - | 2 | - |
10 | F | F | 43 | T-Uni | 18 | R | ++ | + | + | 4 | - |
11 | M | F-B | 49 | A | 3 | Und | Und | - | - | 1.5 | p.Gly2019Ser |
12 | F | Mt | 48 | A | 11 | P | + | - | - | 2 | - |
13 | M | F | 37 | Dy | 15 | P | ++ | + | + | 4 | p.Gly2019Ser |
14 | M | - | 21 | A | 4 | Und | Und | - | - | 1.5 | - |